RxDoctor Payments Data

Tabitha Garrison

Pain Medicine · Broadway, VANPI 1205990983

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 324 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,462, more than ten times the $53 reported in 2020.

$5,111in general payments, 2019–2025

Across 324 payments — averaging $15.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$1K
  • Pfizer$731
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$392
  • Biohaven Pharmaceutical Holding Company Ltd.$387
  • AbbVie$327
  • Boston Scientific$229
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$5,111100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,111 in reported general payments places this provider in the 75th percentile of 150 pain medicine providers in Virginia.

See all pain medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$95,181
Medicare patients
168
Services billed
1,938

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate389$240,711
Nucynta ErTapentadol Hcl111$120,263
BelbucaBuprenorphine Hcl149$115,398
OxycontinOxycodone Hcl157$93,484
RelistorMethylnaltrexone Bromide28$64,952
NucyntaTapentadol Hcl30$42,161
Nurtec OdtRimegepant Sulfate29$35,059
Fentanyl250$28,491
Emgality PenGalcanezumab-Gnlm38$27,569
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen905$26,170
Pregabalin894$22,209
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen767$21,982
Oxycodone Hcl946$20,846
Aimovig AutoinjectorErenumab-Aooe25$18,913
Pregabalin ErPregabalin63$15,273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta Er, Belbuca, Nucynta$1,045$518,533679 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$392$64,95228 claims
PfizerNurtec Odt$731$35,05929 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity, Trintellix$148$19,54738 claims
Scilex Pharmaceuticals Inc.Ztlido$67$15,02014 claims
Redhill Biopharma Inc.Movantik$36$11,19624 claims
Hikma Pharmaceuticals USABuprenorphine$98$8,64238 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 150 pain medicine providers in Virginia.

Other pain medicine in Broadway

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →